loading page

Mortality and disease severity among COVID-19 patients with hypertension receiving renin-angiotensin system inhibitors
  • Syed Shahzad HasanOrcid,
  • Chia Siang Kow,
  • Hamid Merchant
Syed Shahzad Hasan
Orcid
University of Huddersfield
Author Profile
Chia Siang Kow
International Medical University
Author Profile
Hamid Merchant
University of Huddersfield
Author Profile

Abstract

The use of renin-angiotensin system (RAS) inhibitors, including angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), is alleged to cause a more severe course of novel coronavirus disease 2019 (COVID-19). We systematically reviewed the available studies to assess the association of RAS inhibitors with mortality as well as disease severity in COVID-19 patients. A systematic literature search was performed to retrieve relevant original studies investigating mortality and severity (critical disease) in COVID-19 patients with and without exposure to ACEIs/ARBs. A total of 13 original studies were included; 11 studies reporting on mortality and 10 studies reporting on disease severity in ACEI/ARB exposed and unexposed groups. Among hypertensive COVID-19 patients, the use of ACEI/ARB was associated with a significant reduction in the risk of mortality exhibiting a pooled relative risk of 0.73 (95% confidence interval: 0.63-0.86). Moreover, there was no significant difference in the risk of developing severe/critical COVID-19 disease between ACEI/ARB and non-ACEI/ARB groups showing relative risk of 0.72 (95% confidence interval: 0.46-1.12). The data indicate that the use of ACEI/ARB was associated with reduced risk of mortality in COVID-19 patients taking these medications to manage their hypertension.